SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: arnie h who wrote (1336)11/14/2001 9:26:21 AM
From: Icebrg  Read Replies (2) of 10345
 
I just stumbled over the following press release. Which motivates the question. I have been looking for a "list" over all the different collaborations Elan is maintaining. In my opinion a very interesting aspect of the company's activities. But I have not been able to find such a specification. (Perhaps I have not been trying hard enough). Can anyone direct me to such a list?

Inex Pharma Expands Onco TCS Clinical Devt Program

Dow Jones Newswires

VANCOUVER -- Inex Pharmaceuticals Corp. (T.IEX) is expanding the clinical-development program to include two pilot Phase II clinical trials evaluating its Onco TCS product in combination with the approved cancer drug etoposide as a treatment for patients with non-Hodgkin's lymphoma.

In a press release, the company said Onco TCS is being developed under a collaboration agreement with Elan Corp. (ELN).

The company said the Onco TCS-Etoposide Phase II trials are the second set of pilot studies in patients that the company has initiated in 2001. The first set of pilot studies began Sept. 5, evaluating Onco TCS in combination with the approved cancer drug Rituxan (rituximab).

The Onco TCS-Etoposide pilot Phase II clinical trials will evaluate Onco TCS in 35 patients with relapsed aggressive NHL. The primary objectives of the study will be to generate safety data of the combination of etoposide and Onco TCS and to generate preliminary efficacy data. The first of the pilot trials has begun at Norfolk and Norwich University Hospital, England. The second pilot trial will be conducted at three centers in the U.S.

INEX is a biopharmaceutical company.

Company Web Site: inexpharm.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News